What's Driving Bayer's Recent Stock Volatility

Key Takeaways

• Bayer's multi-pronged strategy to contain Roundup litigation hinges on a new $7.25 billion class-action settlement and a pivotal U.S. Supreme Court hearing in April 2026.
• A favorable Supreme Court ruling on federal preemption could significantly reduce future liabilities, but the company still grapples with over 60,000 unresolved lawsuits and substantial financial strain.
• While the stock has seen recent volatility, the long-term investment thesis for BAYRY remains heavily tied to the outcome of this legal battle and the company's ability to pivot away from glyphosate.